Open Orphan PLC Comment regarding press speculation (5092Z)

TIDMORPH

RNS Number : 5092Z

Open Orphan PLC

15 September 2022

Open Orphan plc

("Open Orphan" or the "Company")

Press Speculation

Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the media report relating to the allegation of an incident of potential insider dealing in the Company's shares by an unconnected private individual in 2020.

The Company confirms that it was made aware of this allegation by, and at their request, is helping the relevant Irish authorities in respect of this allegation.

The Board of Open Orphan is satisfied that there are no implications for the Company in the resolution of this allegation and confirms that no employee, executive, director or anyone connected with the Company had any involvement whatsoever in this matter nor are they suspected of any wrongdoing.

For further information please contact:

 
 Open Orphan plc                                                                      [phone] 
 Yamin Khan, Chief Executive Officer 
 
 Liberum Capital (Nominated Adviser and Joint Broker)                                 [phone] 
 Ben Cryer/ Edward Mansfield/ Phil Walker/ Will King 
 
 finnCap plc (Joint Broker)                                                           [phone] 
 Geoff Nash / James Thompson / Richard Chambers 
 
 Davy (Euronext Growth Adviser and Joint Broker)                                       [phone] 
 Anthony Farrell 
 
 Walbrook PR (Financial PR & IR)                          [phone] or [e-mail] 
 Stephanie Cuthbert / Phillip Marriage /                     [phone] / [phone] / 
 Louis Ashe-Jepson                                                                    [phone] 
 
 

Notes to Editors

Open Orphan plc (London and Euronext: ORPH) is a rapidly growing contract research company that is a world leader in testing infectious and respiratory disease products using human challenge clinical trials. The Company provides services to Big Pharma, biotech, and government/public health organisations.

The Company has a leading portfolio of human challenge study models for infectious and respiratory diseases, including the recently established COVID-19 model, and is developing a number of new models, such as Malaria, to address the dramatic growth of the global infectious disease market. The Paris and Breda offices have over 25 years of experience providing drug development services such as biometry, data management, statistics CMC, PK and medical writing to third party clients as well as supporting the London-based challenge studies.

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its newly opened clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester. The newly opened facilities have expanded the scope of the business to enable the offering of Phase I and Phase II vaccine field trials, PK studies, bridging studies, and patient trials as part of large international multi-centre studies.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

SPCUSRBRUVUKAAR

(END) Dow Jones Newswires

September 15, 2022 02:00 ET (06:00 GMT)